OBIZUR

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

3 competitors in Acquired Hemophilia

#DrugCompanyPhaseTrials

1

Hemlibra

Roche

Phase 2

22

OBIZUR

Takeda

Preclinical

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Acquired Hemophilia2 trials

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Completed·BBaxalta now part of Shire··NCT02610127·53 enrolled

Post-Marketing Surveillance (Use-result Surveillance) of OBIZUR Injection [Susoctocog Alpha (Porcine Antihemophilic Factor VIII, Recombinant)] for the Approved Indications in South Korea

Recruiting·Takeda··NCT06550882·9 enrolled

Effectiveness1 trial

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Completed·BBaxalta now part of Shire··NCT03199794·50 enrolled

Details

Drug Info

Related News